16 May 2020, Naarden, The Netherlands – Phlox Therapeutics, a biotech spin-off of the Amsterdam University Medical Center founded by prof. dr. Yigal Pinto and prof. dr. Eva van Rooij, with Margien Boels, PhD as its initiating director of operations have...
Location: Naarden, The Netherlands Duration: 6-9 months About BGV Since our inception in 2006, BGV has raised four early-stage biotech funds totaling over €250 million in capital. Our portfolio is focused on novel therapeutics across different treatment modalities and...
Amsterdam, The Netherlands, and Boston, MA, USA – 30 March 2022 – Scenic Biotech BV (‘Scenic’ or ‘the Company’), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and...
– Second Orphan Drug Designation Supports Azafaros’ Strategy to Develop AZ-3102 as a Disease Modifying Treatment in a Range of Severe Rare Inherited Metabolic Disorders – Leiden, The Netherlands, March 24, 2022 – Azafaros B.V. today announced that the US Food...
Ghent, Belgium – March 10, 2022 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that the first subjects have been dosed in the company’s Phase 1, first-in-human trial of their clinical...
Amsterdam, The Netherlands, 10 March 2022 – Scenic Biotech BV (“Scenic”), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, is pleased to...
